Targeting P2X7 receptors as a means for treating retinal disease

Erica L. Fletcher, Anna Y. Wang, Andrew I. Jobling, Matthew V. Rutar, Ursula Greferath, Ben Gu, Kirstan A. Vessey

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood–brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.

Original languageEnglish
Pages (from-to)1598-1605
Number of pages8
JournalDrug Discovery Today
Volume24
Issue number8
DOIs
Publication statusPublished - Aug 2019
Externally publishedYes

Fingerprint Dive into the research topics of 'Targeting P2X7 receptors as a means for treating retinal disease'. Together they form a unique fingerprint.

Cite this